Ligand Pharmaceuticals (LGND) Debt/Assets Ratio: History & Chart

Ligand Pharmaceuticals Incorporated(LGND)

Biotechnology · Jupiter, FL

$295.91-10.86 (-3.54%)

Delayed quote: Oct 6, 2026, 1:15 PM EDT

About Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.

Jupiter, FL

47 employees

www.ligand.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Todd C. Davis

View full financials

LGND Debt to Assets Ratio Metrics

DEBT TO ASSETS RATIO

51.76%

DEBT TO ASSETS RATIO AVG TTM

28.27%

DEBT TO ASSETS RATIO AVG 3Y

11.39%

DEBT TO ASSETS RATIO AVG 5Y

13.76%

DEBT TO ASSETS RATIO AVG 10Y

24.90%

DEBT TO ASSETS RATIO AVG 15Y

28.68%

DEBT TO ASSETS RATIO AVG 20Y

27.30%

CURRENT VS TTM AVG

+83.12%

CURRENT VS 3Y AVG

+354.51%

CURRENT VS 5Y AVG

+276.06%

CURRENT VS 10Y AVG

+107.88%

CURRENT VS 15Y AVG

+80.47%

CURRENT VS 20Y AVG

+89.57%

SECTOR MEDIAN · HEALTHCARE

0.09%

median of 809 covered companies

CURRENT VS SECTOR MEDIAN

+57413.35%

vs the sector median at left

NAME	MARKET CAP	DEBT TO ASSETS RATIO	TTM	3Y	5Y
Ligand Pharmaceuticals Incorporated (LGND)	$5.93B	51.76%	28.27%	11.39%	13.76%
Iovance Biotherapeutics, Inc. (IOVA)vs ›	$5.92B	0.05%	N/A	N/A	N/A
GRAIL Inc. (GRAL)vs ›	$6.03B	0.03%	N/A	N/A	N/A
Kodiak Sciences Inc. (KOD)vs ›	$5.82B	0.37%	N/A	N/A	N/A
Kiniksa Pharmaceuticals International, plc (KNSA)vs ›	$5.75B	0.01%	N/A	N/A	N/A
Rhythm Pharmaceuticals, Inc. (RYTM)vs ›	$6.20B	0.01%	N/A	N/A	N/A
CG Oncology Inc. (CGON)vs ›	$5.62B	0.01%	N/A	N/A	N/A
RadNet, Inc. (RDNT)vs ›	$5.53B	0.52%	N/A	N/A	N/A
MiniMed Group, Inc. Common Stock (MMED)vs ›	$5.52B	0.01%	N/A	N/A	N/A
Amneal Pharmaceuticals, Inc. (AMRX)vs ›	$6.49B	0.74%	N/A	N/A	N/A

NAME

MARKET CAP

DEBT TO ASSETS RATIO

TTM

Ligand Pharmaceuticals Incorporated (LGND)

$5.93B

51.76%

28.27%

11.39%

13.76%

Iovance Biotherapeutics, Inc. (IOVA)vs ›

$5.92B

0.05%

N/A

GRAIL Inc. (GRAL)vs ›

$6.03B

0.03%

N/A

Kodiak Sciences Inc. (KOD)vs ›

$5.82B

0.37%

N/A

Kiniksa Pharmaceuticals International, plc (KNSA)vs ›

$5.75B

0.01%

N/A

Rhythm Pharmaceuticals, Inc. (RYTM)vs ›

$6.20B

0.01%

N/A

CG Oncology Inc. (CGON)vs ›

$5.62B

0.01%

N/A

RadNet, Inc. (RDNT)vs ›

$5.53B

0.52%

N/A

MiniMed Group, Inc. Common Stock (MMED)vs ›

$5.52B

0.01%

N/A

Amneal Pharmaceuticals, Inc. (AMRX)vs ›

$6.49B

0.74%

N/A

Debt to Assets Ratio FAQ

What is the debt to assets ratio for Ligand Pharmaceuticals Incorporated (LGND)?

The debt to assets ratio for LGND stock is 51.76%.

Is Ligand Pharmaceuticals Incorporated's debt to assets ratio high or low?

The debt to assets ratio of 51.76% is 276% above its 5-year average of 13.76%, near the high end of its 5-year range (0.49%–51.76%).

What is the TTM average debt to assets ratio for Ligand Pharmaceuticals Incorporated (LGND)?

The TTM average debt to assets ratio for LGND stock is 28.27%.

What is the 3Y average debt to assets ratio for Ligand Pharmaceuticals Incorporated (LGND)?

The 3Y average debt to assets ratio for LGND stock is 11.39%.

What is the 5Y average debt to assets ratio for Ligand Pharmaceuticals Incorporated (LGND)?

The 5Y average debt to assets ratio for LGND stock is 13.76%.

What is the 10Y average debt to assets ratio for Ligand Pharmaceuticals Incorporated (LGND)?

The 10Y average debt to assets ratio for LGND stock is 24.90%.

What is the 15Y average debt to assets ratio for Ligand Pharmaceuticals Incorporated (LGND)?

The 15Y average debt to assets ratio for LGND stock is 28.68%.

What is the 20Y average debt to assets ratio for Ligand Pharmaceuticals Incorporated (LGND)?

The 20Y average debt to assets ratio for LGND stock is 27.30%.

DATE	DEBT TO ASSETS RATIO
2026-06-30	51.76%
2026-03-31	29.50%
2025-12-31	28.93%
2025-09-30	30.54%
2025-06-30	0.61%
2025-03-31	0.49%
2024-12-31	0.75%
2024-09-30	0.77%
2024-06-30	0.88%
2024-03-31	0.68%
2023-12-31	0.78%
2023-09-30	0.82%
2023-06-30	1.54%
2023-03-31	10.93%
2022-12-31	11.51%
2022-09-30	10.84%
2022-06-30	13.44%
2022-03-31	17.66%
2021-12-31	25.00%
2021-09-30	25.96%
2021-06-30	25.66%
2021-03-31	28.26%
2020-12-31	33.50%
2020-09-30	36.87%
2020-06-30	37.06%
2020-03-31	38.38%
2019-12-31	43.49%
2019-09-30	41.51%
2019-06-30	36.78%
2019-03-31	33.92%
2018-12-31	50.47%
2018-09-30	38.75%
2018-06-30	43.39%
2018-03-31	30.15%
2017-12-31	33.46%
2017-09-30	33.45%
2017-06-30	34.16%
2017-03-31	34.26%
2016-12-31	35.39%
2016-09-30	34.97%
2016-06-30	33.62%
2016-03-31	33.36%
2015-12-31	38.46%
2015-09-30	38.90%
2015-06-30	65.81%
2015-03-31	75.44%
2014-12-31	76.05%
2014-09-30	71.24%
2014-06-30	2.70%
2014-03-31	5.47%
2013-12-31	8.70%
2013-09-30	12.17%
2013-06-30	15.64%
2013-03-31	19.02%
2012-12-31	27.12%
2012-09-30	38.63%
2012-06-30	52.28%
2012-03-31	36.00%
2011-12-31	24.75%
2011-09-30	55.54%
2011-06-30	31.37%
2011-03-31	30.47%
2010-12-31	30.24%
2010-09-30	38.81%
2010-06-30	38.39%
2010-03-31	29.12%
2009-12-31	25.64%
2009-09-30	49.08%
2009-06-30	44.85%
2009-03-31	41.84%
2008-12-31	2.34%
2008-09-30	0.60%
2008-06-30	0.78%
2008-03-31	0.99%
2007-12-31	1.24%
2007-09-30	1.28%
2007-06-30	1.42%
2007-03-31	0.72%
2006-12-31	12.24%
2006-09-30	61.43%
2006-06-30	50.65%
2006-03-31	50.73%
2005-12-31	54.96%
2005-09-30	56.53%
2005-06-30	57.60%
2005-03-31	55.58%
2004-12-31	52.34%
2004-09-30	60.34%
2004-06-30	59.59%
2004-03-31	59.01%
2003-12-31	57.27%
2003-09-30	56.91%
2003-06-30	72.56%
2003-03-31	65.24%
2002-12-31	58.14%
2002-09-30	13.52%

DATE

DEBT TO ASSETS RATIO

2026-06-30

51.76%

2026-03-31

29.50%

2025-12-31

28.93%

2025-09-30

30.54%

2025-06-30

0.61%

2025-03-31

0.49%

2024-12-31

0.75%

2024-09-30

0.77%

2024-06-30

0.88%

2024-03-31

0.68%

2023-12-31

0.78%

2023-09-30

0.82%

2023-06-30

1.54%

2023-03-31

10.93%

2022-12-31

11.51%

2022-09-30

10.84%

2022-06-30

13.44%

2022-03-31

17.66%

2021-12-31

25.00%

2021-09-30

25.96%

2021-06-30

25.66%

2021-03-31

28.26%

2020-12-31

33.50%

2020-09-30

36.87%

2020-06-30

37.06%

2020-03-31

38.38%

2019-12-31

43.49%

2019-09-30

41.51%

2019-06-30

36.78%

2019-03-31

33.92%

2018-12-31

50.47%

2018-09-30

38.75%

2018-06-30

43.39%

2018-03-31

30.15%

2017-12-31

33.46%

2017-09-30

33.45%

2017-06-30

34.16%

2017-03-31

34.26%

2016-12-31

35.39%

2016-09-30

34.97%

2016-06-30

33.62%

2016-03-31

33.36%

2015-12-31

38.46%

2015-09-30

38.90%

2015-06-30

65.81%

2015-03-31

75.44%

2014-12-31

76.05%

2014-09-30

71.24%

2014-06-30

2.70%

2014-03-31

5.47%

2013-12-31

8.70%

2013-09-30

12.17%

2013-06-30

15.64%

2013-03-31

19.02%

2012-12-31

27.12%

2012-09-30

38.63%

2012-06-30

52.28%

2012-03-31

36.00%

2011-12-31

24.75%

2011-09-30

55.54%

2011-06-30

31.37%

2011-03-31

30.47%

2010-12-31

30.24%

2010-09-30

38.81%

2010-06-30

38.39%

2010-03-31

29.12%

2009-12-31

25.64%

2009-09-30

49.08%

2009-06-30

44.85%

2009-03-31

41.84%

2008-12-31

2.34%

2008-09-30

0.60%

2008-06-30

0.78%

2008-03-31

0.99%

2007-12-31

1.24%

2007-09-30

1.28%

2007-06-30

1.42%

2007-03-31

0.72%

2006-12-31

12.24%

2006-09-30

61.43%

2006-06-30

50.65%

2006-03-31

50.73%

2005-12-31

54.96%

2005-09-30

56.53%

2005-06-30

57.60%

2005-03-31

55.58%

2004-12-31

52.34%

2004-09-30

60.34%

2004-06-30

59.59%

2004-03-31

59.01%

2003-12-31

57.27%

2003-09-30

56.91%

2003-06-30

72.56%

2003-03-31

65.24%

2002-12-31

58.14%

2002-09-30

13.52%

Debt to Assets Ratio: 51.76%

LGND Debt to Assets Ratio

LGND Average Debt to Assets Ratio Chart

LGND Current vs Average Debt to Assets Ratio Chart

LGND Debt to Assets Ratio Metrics

LGND Competitors' Debt to Assets Ratio

Leverage Ratios Comparison

Debt to Assets Ratio Formula & Definition

Debt to Assets Ratio FAQ

LGND Debt to Assets Ratio History

Related Metrics